Van Etten E, Branisteanu D D, Overbergh L, Bouillon R, Verstuyf A, Mathieu C
Laboratory of Experimental Medicine and Endocrinology, Catholic University of Leuven, Herestraat 49, Belgium.
Bone. 2003 Apr;32(4):397-404. doi: 10.1016/s8756-3282(03)00030-9.
The vitamin D analog TX527 (19-nor-14,20-bis epi-23-yne-1,25(OH)(2)D(3)), decreased disease severity (P < 0.001) and postponed disease onset (P < 0.0001) in SJL mice in which experimental autoimmune encephalomyelitis was induced. Levels of IFN-gamma and IL-2 mRNA were decreased in spinal cord and spleen in the analog-treated mice, suggesting a Th(1)-targeted effect. Adding the bisphosphonate pamidronate did not affect analog-protective efficacy, but completely prevented TX527-caused acceleration of bone turnover and increased total bone mineral content as well as femoral mineral and calcium content (P < 0.01). Less calcemic analogs of 1,25-dihydroxyvitamin D(3), in combination with bone sparing products such as bisphosphonates allow immune modulation in vivo without affecting bone.
维生素D类似物TX527（19-去甲-14,20-双表-23-炔-1,25(OH)₂D₃）可减轻诱导实验性自身免疫性脑脊髓炎的SJL小鼠的疾病严重程度（P < 0.001）并延缓疾病发作（P < 0.0001）。在接受类似物治疗的小鼠的脊髓和脾脏中，IFN-γ和IL-2 mRNA水平降低，提示有针对Th1的效应。添加双膦酸盐帕米膦酸并不影响类似物的保护效果，但能完全防止TX527引起的骨转换加速，并增加骨矿物质总量以及股骨矿物质和钙含量（P < 0.01）。1,25-二羟基维生素D₃的低钙血症类似物与双膦酸盐等保骨产品联合使用，可在不影响骨骼的情况下在体内调节免疫。
